Contact Me
My Company Litesprite

Role(s) in Healthcare Innovation:

Healthcare Innovator

Swatee Surve, MS Mechanical Engineering, MBA

Litesprite


University of Chicago, Pennsylvania State U

About Me

Swatee Surve, Founder & CEO. An Indian-American female who created and launched disruptive technology-based healthcare businesses for Microsoft, Nike, T-Mobile, Premera Blue Cross and Eastman Kodak. These commercialization projects led to several patents including Nike's first wearable technology patents. She is one of Puget Sound Business Journal’s Innovators of the Year. She is recognized as an international healthcare leader by organizations such as the U.S. State Department. Her essay on “Embracing the science of behavior change” will be included in HIMSS’s Medical Informatics 4th ed. Surve has an MBA from the University of Chicago, an MSME in Biomechanics from Pennsylvania State University, and a BS in Bioengineering from the University of Illinois at Chicago. She has been featured in international, national, and regional media outlets. https://www.linkedin.com/in/swatee

You have not backed any projects. Lets change that!
Discover Projects

No comments on any project yet. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No data found. Lets change that!
Discover Projects

No project reviewed yet. Lets change that!
Discover Projects

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.